Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4404Urinary Bladder Neoplasms 1080Carcinoma, Renal Cell 1042Kidney Neoplasms 568Breast Neoplasms 454Neoplasms 406Carcinoma, Transitional Cell 301Neoplasm Metastasis 251Lung Neoplasms 243Testicular Neoplasms 202Melanoma 196Colorectal Neoplasms 194Ovarian Neoplasms 165Carcinoma, Non-Small-Cell Lung 150Non-Muscle Invasive Bladder Neoplasms 136Sarcoma 135Pancreatic Neoplasms 125Colonic Neoplasms 121Head and Neck Neoplasms 117Uterine Cervical Neoplasms 116Wilms Tumor 108Recurrence 106Motor Activity 100Urologic Neoplasms 90Stomach Neoplasms 89Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 81Adenocarcinoma 79

Interventions

sipuleucel-T 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castrate-resistant Prostate Cancer × Genitourinary × Clear all
NCT01818986 2022-05-06

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

University of Texas Southwestern Medical Center

Phase 2 Completed
20 enrolled 13 charts
Genitourinary

Metastatic Castrate-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡